HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
Breast Cancer Update
00:00
What are next options and trials after multiple ADCs?
Dr Huppert recommends clinical trials, taxane or gem/carbo, and cautious consideration of additional ADCs given cross‑resistance concerns.
Play episode from 34:46
Transcript
